JMP Securities initiated coverage on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $69.00 price target on the stock.
A number of other analysts have also issued reports on CRSP. Piper Jaffray Companies reiterated a buy rating and set a $22.75 price objective (down previously from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday, January 10th. Barclays lifted their price objective on shares of Crispr Therapeutics from $29.00 to $59.00 and gave the company an overweight rating in a research note on Wednesday, March 7th. Citigroup lifted their price objective on shares of Crispr Therapeutics from $20.00 to $51.00 and gave the company a neutral rating in a research note on Wednesday, February 28th. ValuEngine upgraded shares of Crispr Therapeutics from a sell rating to a hold rating in a research note on Wednesday, February 28th. Finally, Cann reiterated a hold rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $53.53.
Shares of Crispr Therapeutics (CRSP) opened at $56.72 on Thursday. Crispr Therapeutics has a 12 month low of $13.50 and a 12 month high of $61.24.
Several hedge funds have recently added to or reduced their stakes in the company. Farallon Capital Management LLC acquired a new stake in shares of Crispr Therapeutics during the fourth quarter worth approximately $20,160,000. Franklin Resources Inc. grew its position in shares of Crispr Therapeutics by 8.9% during the fourth quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after buying an additional 65,200 shares in the last quarter. Global Thematic Partners LLC grew its position in shares of Crispr Therapeutics by 11.2% during the fourth quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after buying an additional 63,611 shares in the last quarter. BlackRock Inc. grew its position in shares of Crispr Therapeutics by 16,623.9% during the fourth quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock worth $12,974,000 after buying an additional 549,254 shares in the last quarter. Finally, Opaleye Management Inc. acquired a new position in Crispr Therapeutics in the fourth quarter worth $6,597,000. 27.29% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2018/03/12/jmp-securities-initiates-coverage-on-crispr-therapeutics-crsp.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.